Major depression and metabolic encephalopathy: Syndromes more alike than not?

0Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The seminal discovery of the antidepressant imipramine in 1958, the mood-stabilizing actions of lithium ion in 1949, and that these drugs work by increasing or modulating synaptic levels of one or more monoamine such as serotonin (5HT), noradrenaline (NA) or dopamine (DA), have set the gold standard for drug research and treatment in mania and depression. However, drug discovery has not realized its full potential and in many ways is decades behind our understanding of psychiatric illness. Our newest drugs for these disorders, such as the 5HT reuptake inhibitors (SRI, e.g., fluoxetine (Prozac®)), are not any more effective than imipramine in the treatment of depression (Geddes et al., 2000) while after more than 50 years, lithium salts still remain the bench mark treatment for manic depression (Compton and Nemeroff, 2000).

Cite

CITATION STYLE

APA

Harvey, B. H. (2009). Major depression and metabolic encephalopathy: Syndromes more alike than not? In Metabolic Encephalopathy (pp. 349–369). Springer New York. https://doi.org/10.1007/978-0-387-79112-8_18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free